Physician profile
Edgar Abovich
NPI 1144242066
$11,188.51
in general payments reported to CMS, 2019-2025
27 companies · $658 in 2025
The $658 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,471 · 2020: $725 · 2021: $2,436 · 2022: $1,858 · 2023: $1,665 · 2024: $1,375 · 2025: $658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,697.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,646.70 | 2019-2024 | Xarelto |
| Amgen INC. | $1,307.36 | 2019-2025 | Repatha, Repatha |
| Medtronic, INC. | $1,129.68 | 2021-2024 | Azure Xt Dr Mri Surescan, Reveal Linq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $900.59 | 2019-2025 | Jardiance |
| Atricure, INC. | $723.43 | 2021-2023 | |
| Abbott Laboratories | $629.50 | 2019-2024 | Amplatzer Amulet |
| Astrazeneca Pharmaceuticals LP | $598.19 | 2019-2025 | Farxiga, Lokelma |
| E.R. Squibb & Sons, L.L.C. | $583.03 | 2019-2025 | Camzyos, Eliquis |
| Amarin Pharma, INC. | $397.66 | 2019-2022 | |
| Esperion Therapeutics, INC. | $353.28 | 2020-2025 | Nexletol |
| Pfizer INC. | $336.39 | 2019-2025 | |
| Abiomed | $295.43 | 2023 | Impella |
| Impulse Dynamics (USA) INC. | $287.93 | 2021 | |
| Silk Road Medical, INC. | $278.77 | 2019-2020 | |
| Biosense Webster, INC. | $273.51 | 2023-2024 | Thermocool Sf, Qdot Micro Catheter |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $254.92 | 2021-2023 | Verquvo |
| Boston Scientific Corporation | $252.28 | 2019-2023 | Watchman Access System |
| Novartis Pharmaceuticals Corporation | $230.29 | 2020-2025 | |
| Edwards Lifesciences Corporation | $198.49 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $150.68 | 2019-2024 | Evkeeza |
| Bayer Healthcare Pharmaceuticals INC. | $114.93 | 2021 | |
| Medtronic Vascular, INC. | $106.53 | 2019 | |
| Sanofi-Aventis U.S. LLC | $61.99 | 2019-2021 | |
| Agepha Pharma Fz LLC | $34.84 | 2024-2025 | Lodoco |
| Novo Nordisk INC | $14.96 | 2023 | Ozempic |
| Kowa Pharmaceuticals America, INC. | $13.98 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edgar Abovich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.